Drug Information

Drug General Information
Drug ID
D03JTG
Former ID
DIB010509
Drug Name
Fruquintinib
Synonyms
HMPL-013
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 3 [525024]
Company
Hutchison Medipharma Enterprises Ltd
Target and Pathway
Target(s) Vascular endothelial growth factor receptor 1 Target Info Inhibitor [533061]
Vascular endothelial growth factor receptor 2 Target Info Inhibitor [533061]
Vascular endothelial growth factor receptor 3 Target Info Inhibitor [533061]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
HIF-1 signaling pathway
Endocytosis
PI3K-Akt signaling pathway
Focal adhesion
Transcriptional misregulation in cancer
Rheumatoid arthritishsa04014:Ras signaling pathway
VEGF signaling pathway
Proteoglycans in cancerhsa04014:Ras signaling pathway
NetPath Pathway IL2 Signaling PathwayNetPath_9:TNFalpha Signaling Pathway
PANTHER Pathway Angiogenesis
VEGF signaling pathway
Pathway Interaction Database Glypican 1 network
HIF-2-alpha transcription factor network
S1P3 pathway
VEGF and VEGFR signaling network
VEGFR1 specific signals
Signaling events mediated by VEGFR1 and VEGFR2hif2pathway:HIF-2-alpha transcription factor network
Beta3 integrin cell surface interactions
Signaling events mediated by TCPTP
SHP2 signaling
S1P1 pathway
Integrins in angiogenesis
Signaling events mediated by VEGFR1 and VEGFR2
Notch-mediated HES/HEY networkvegf_vegfr_pathway:VEGF and VEGFR signaling network
VEGFR3 signaling in lymphatic endothelium
Reactome Neurophilin interactions with VEGF and VEGFR
VEGF binds to VEGFR leading to receptor dimerizationR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
VEGF binds to VEGFR leading to receptor dimerization
Integrin cell surface interactions
EPHA-mediated growth cone collapse
VEGFA-VEGFR2 Pathway
VEGFR2 mediated cell proliferationR-HSA-195399:VEGF binds to VEGFR leading to receptor dimerization
WikiPathways Focal Adhesion
Signaling by VEGF
AngiogenesisWP306:Focal Adhesion
Nifedipine Activity
Cardiac Progenitor Differentiation
AngiogenesisWP1919:Signaling by VEGF
References
Ref 525024ClinicalTrials.gov (NCT02314819) A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients ???RESCO). U.S. National Institutes of Health.
Ref 533061Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.